Latest news with #Cerus
Business Wire
3 days ago
- Business
- Business Wire
Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced it will showcase the latest INTERCEPT Blood System clinical data at the 35 th Regional International Society of Blood Transfusion (ISBT) Congress being held May 31 to June 4, 2025, in Milan. 'The breadth of data being presented this year underscores the broad applicability of the INTERCEPT system for platelets, plasma, and cryoprecipitated fibrinogen complex as well as the potential benefit for red blood cells,' said Richard J. Benjamin, Cerus' chief medical officer. 'Importantly, we are looking forward to sharing the positive results from our Phase 3 ReCePI study in red blood cells, INTERCEPT treated cold stored platelets, and effective inactivation of California encephalitis virus with the blood transfusion community.' The following is a list of selected presentations and abstracts of interest for Cerus. All presentation times are listed in Central European Summer Time (CEST). The full program of Cerus-related abstracts can be found at the following link: Cerus Sponsored Symposium INTERCEPT™ - Much more than just Pathogen Inactivation Use of INTERCEPT platelet concentrates in France: impact on adverse events, platelet use and inventory management INTERCEPT platelets: Impact on the occurrence of pulmonary adverse events in haematology-oncology patients Safety and Efficacy of INTERCEPT treated platelets transfused to mature and premature neonates Oral Presentations Monday, June 2, 2025 – 09:45 – 10:00 - Cold-stored amotosalen-UVA pathogen-reduced platelet concentrates display distinct platelet subpopulations with specific functional properties Monday, June 2, 2025 – 14:15 – 14:30 - Reduced hemoglobin use with amustaline/glutathione pathogen-reduced red cells in complex cardiac surgery: results of a randomized, controlled Phase III trial Monday, June 2, 2025 – 16:15 – 16:30 - Surface-bound acridine as a novel marker to track entire units of transfused pathogen-reduced red cells in sickle cell patients Selected Poster Presentations Monday, June 2, 2025 – 17:15 – 18:15 P220: Evaluation of Whole Blood Plasma Pool Stability After Treatment for Pathogen Reduction With Amotosalen/A Prototype LED Illuminator and 2 Years of Storage P276: In Vitro Evaluation of Cold Stored and Room Temperature Double Dose Platelets Treated With Amotosalen and UVA Light P279: Hemostatic Functions of Platelets and Their Subpopulations According to Platelet Concentrate Storage Conditions, Assessed by Viscoelastic Platform P287: Pathogen Reduced Cryoprecipitated Fibrinogen Complex Supports Collagen-Mediated Platelet Adhesion and Thrombus Formation of Pathogen-Reduced Platelet Components Stored Up to Seven Days P307: Inactivation of California Encephalitis Virus in Platelet Concentrates Using Amotosalen and UVA Treatment P472: Investigations into the Clinical Significance of Treatment-Emergent Antibodies to Amustaline/Glutathione Pathogen-Reduced Red Blood Cells ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Yahoo
24-05-2025
- Business
- Yahoo
When Should You Buy Cerus Corporation (NASDAQ:CERS)?
While Cerus Corporation (NASDAQ:CERS) might not have the largest market cap around , it received a lot of attention from a substantial price movement on the NASDAQGM over the last few months, increasing to US$1.86 at one point, and dropping to the lows of US$1.22. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Cerus' current trading price of US$1.25 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Cerus's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. According to our valuation model, Cerus seems to be fairly priced at around 11% below our intrinsic value, which means if you buy Cerus today, you'd be paying a fair price for it. And if you believe that the stock is really worth $1.40, then there's not much of an upside to gain from mispricing. So, is there another chance to buy low in the future? Given that Cerus's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us an opportunity to buy later on. This is based on its high beta, which is a good indicator for share price volatility. See our latest analysis for Cerus Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. With profit expected to grow by a double-digit 12% in the upcoming year, the short-term outlook is positive for Cerus. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation. Are you a shareholder? CERS's optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven't considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value? Are you a potential investor? If you've been keeping tabs on CERS, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it's worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example, we've discovered 2 warning signs that you should run your eye over to get a better picture of Cerus. If you are no longer interested in Cerus, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-02-2025
- Business
- Yahoo
Cerus Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Revenue: US$180.3m (up 15% from FY 2023). Net loss: US$20.9m (loss narrowed by 44% from FY 2023). US$0.11 loss per share (improved from US$0.21 loss in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 7.0%. Earnings per share (EPS) exceeded analyst estimates by 1.8%. Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Performance of the American Medical Equipment industry. The company's shares are down 11% from a week ago. What about risks? Every company has them, and we've spotted 1 warning sign for Cerus you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
